News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma AB (publ) Interim report January – June 2012

August 24, 2012

PledPharma AB
Interim information

PledPharma AB (publ) Interim report January – June 2012

PledOx™ clinical study design approved

Stockholm, 2012-08-24 08:30 CEST (GLOBE NEWSWIRE) -- 

The period April – June

·      Net result amounted to SEK -10 548k (-2 488k)

·      Cash flow from operating activities amounted to SEK -13 038k ( 1 837k)

·      Result per share amounted to SEK -0.52 (-0.19)

Significant events after the end of the period

·      The design of the clinical study for PledOx was approved by the Swedish
Medical Products Agency (MPA) August 1 

·      Professor Bengt Glimelius at Uppsala University Hospital, a world
authority within research and treatment of cancer, especially cancer in the
gastrointestinal canal, coordinating principal investigator of the PledOx study 

·      Positive results achieved in the long term preclinical PledOx safety

·      A new composition of matter patent application for PledOx provides
additional strong and extended patent protection opportunities 

The first half Year in summary

·      Net result amounted to SEK -19 825k (-5 336k)

·      Cash flow from operating activities amounted to SEK -21 889k (-1 625k)

·      Cash and cash equivalents on June 30 was SEK 68 608k (106 165k)

·      Result per share amounted to SEK -0.98 (-0.40)

·      Positive and supportive meetings with the MPA and the US regulatory
authority (FDA) regarding the PledOx study 

·      Publication of clinical study, showing a decreased number of serious
incidences due to chemotherapy in patients pretreated with PLED-substance, in a
scientific journal 

CEO comments

“We are very pleased to have delivered all necessary interim goals necessary to
initiate our important clinical PledOx Phase IIb trial in colorectal cancer
patients. The study design is now approved by the Swedish MPA and we expect to
recruit the first patient in September/October 2012. This is a very important
milestone in the development of the company”, says CEO Jacques Näsström. 

For further information contact:
Erik Kinnman, VP Investor Relations, cell + 46 73 422 15 40

Johan Stuart, CFO, cell +46 70 66 44 096

Jacques Näsström, CEO cell +46 73 713 09 79

About PledPharma

PledPharma is a Swedish specialty pharma company that develops a new medicine,
PledOx™, for prevention of the severe side effects that patients develop as a
consequence of chemotherapy treatment of cancer. Many times the treatment
cannot be carried out as planned due to very difficult side effects. The
current market for supportive cancer care is some SEK 72 billion. PledOx is a
medicine within the patent protected substance class PLED, which protects the
body’s normal cells against oxidative stress. Oxidative stress is a condition
where an overabundance of harmful oxygen molecules (free oxygen radicals) has
been formed. We are also evaluating opportunities with PLED substances for
other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik
Penser Bankaktiebolag is the Certified Adviser. For more information, please



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10